Preclinical
January 29, 2025
Tumor Models Summit
Leveraging Humanized Mouse Models to Support T-Cell Engager Development
Nichole Escalante
Preclinical
January 29, 2025
Tumor Models Summit
TriTCE Co-Stim: A trispecific T cell engager platform with integrated CD28 co-stimulation to improve T cell function and anti-tumor responses in hard-to-treat cancers
Diana Canals Hernaez
Preclinical
January 15, 2025
PepTalk
Parallelization of Paratope Optimization and Antibody Format Screening for Efficient Characterization and Development of Multispecific T Cell Engagers
Meghan Verstraete
Preclinical
November 9, 2024
SITC
Mechanistic QSP modeling and translational strategy for determining an FIH dose for ZW171, a bispecific 2+1 T-cell engager molecule targeting mesothelin and CD3
Charles Chen
Preclinical
November 5, 2024
PEGS
Azymetric Fc-based Therapeutic Modalities Enabling Tumor-Restricted Immune Cell Activation and Engagement
Thomas Spreter von Kreudenstein
Preclinical
October 25, 2024
AACR-EORTC-NCI
ZW220, a NaPi2b-directed TOPO1i ADC, demonstrates compelling preclinical activity in NSCLC, ovarian and uterine cancer models, with a favorable toxicology profile in NHPs
Andrea Hernández Rojas
Preclinical
October 24, 2024
AACR-EORTC-NCI
Beyond ADC Target Expression: Understanding ADC Properties and Pharmacology
Raffaele Colombo
Preclinical
October 23, 2024
Cancer Discovery
The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development
Colombo et al.
Preclinical
October 23, 2024
AACR-EORTC-NCI
ZW251, a novel glypican-3-targeting antibody-drug conjugate bearing a topoisomerase I inhibitor payload, demonstrates compelling preclinical activity in hepatocellular carcinoma models
Madera et al.
Preclinical
August 21, 2024
ACS
Design and selection of the novel camptothecin analog ZD06519: A payload optimized for antibody-drug conjugates
Brant et al.
Preclinical
August 7, 2024
Immuno-Oncology Summit
Building Differentiated & Next Generation T Cell Engagers to Improve Responses in Difficult-to-Treat Tumors.
Nicole Afacan
Preclinical
June 23, 2024
ADCS National Medicinal Chemistry Symposium
Development of a Novel TOPO1i ADC Platform: From Concept to Pipeline Application
Mark Petersen
